Buccal delivery of fluorescein isothiocyanate-dextran 4400 and the peptide drug buserelin with glycodeoxycholate as an absorption enhancer in pigs

Journal of Controlled Release

Volumn 41, Issue 1-2, 1996, Pages 77-84

  Hoogstraate, A J ^a   Verhoef, J C ^a,c   Tuk, B ^a   Pijpers, A ^b   Van Leengoed, L A M G ^b   Verheijden, J H M ^b   Junginger, H E ^a   Bodde H E ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Bile salts; Buccal administration; Buserelin; Fluorescein isothiocyanate labelled dextran 4400

Indexed keywords

BUSERELIN; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; GLYCODEOXYCHOLIC ACID; PENETRATION ENHANCING AGENT; PEPTIDE;

ANIMAL EXPERIMENT; CHEEK MUCOSA; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; HYDROPHILICITY; INTRAVENOUS DRUG ADMINISTRATION; MACROMOLECULE; MALE; MEMBRANE PERMEABILITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STEADY STATE; SWINE;

EID: 0030222223     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-3659(96)01358-2     Document Type: Conference Paper

References (30)

1. [1] V.H.L. Lee, Enzymatic barriers to peptide and protein absorption and the use of penetration enhancers to modify absorption, in: S.S. Davis, L. Illum and E. Tomlinson (Eds.), Delivery System for Peptide Drugs, Plenum Press, New York 1986, pp. 87-104.
2. [2] M.E. De Vries, Buccal drug absorption and development of mucoadhesive polymer systems, PhD thesis. University of Leiden, The Netherlands, 1991.
3. [3] M. Gibaldi and J.L. Kanig, Absorption of drugs through the oral mucosa, J. Oral Ther. Pharmacol. 1 (1965) 440-450.
4. [4] I.A. Siegel, Permeability of the oral mucosa, In: J. Meyer, C.A. Squier and S.J. Gerson (Eds.), The Structure and Function of Oral Mucosa, Pergamon Press, Oxford, 1984, pp. 95-108.
5. [5] C.A. Squier, The permeability of oral mucosa, Crit. Rev. Oral Biol. Med. 2 (1991) 13-32.
6. [6] M.J. Rathbone and J. Hadgraft, Absorption of drugs from the human oral cavity. Int. J. Pharm. 74 (1991) 9-24.
7. [7] M.E. De Vries, H.E. Boddé. J.C. Verhoef and H.E. Junginger, Developments in buccal drug delivery, Crit. Rev. Ther. Drug Carrier Syst. 8 (1991) 271-303.
8. [8] H.P. Merkle and G. Wolany, Buccal delivery for peptide drugs, J. Control. Release 21 (1992) 155-164.
9. [9] T. Nagai, Adhesive topical drug delivery systems, J. Control. Release 2 (1985) 121-134.
10. [10] W. Schurr, B. Knoll, R. Ziegler, R. Anders and H.P. Merkle, Comparative study of intravenous, nasal, oral and buccal TRH administration among healthy subjects, J. Endocrinol. Invest. 8 (1985) 41-44.
11. [11] R. Anders, H.P. Merkle, W. Schurr and R. Ziegler, Buccal absorption of protirelin: an effective way to stimulate thyrotropin and prolactin, J. Pharm. Sci. 72 (1983) 1481-1483.
12. [12] B.J. Aungst and N.J. Rogers, Comparison of the effects of various transmucosal absorption promoters on buccal insulin delivery, Int. J. Pharm. 53 (1989) 227-235.
13. [13] J. Zhang, S. Niu, C. Ebert and T.H. Stanley, An in-vivo dog model for studying recovering kinetics of the buccal mucosa permeation barrier after exposure to permeation enhancers: apparent evidence of effective enhancement without tissue damage, Int. J. Pharm. 101 (1994) 15-22.
14. [14] C.K. Oh and W.A. Ritschel, Biopharmaceutical aspects of buccal absorption of insulin, Methods Find. Exp. Clin. Pharmacol. 12 (1990) 205-212.
15. [15] A. Steward, D.L. Bayley and C. Howes, The effect of enhancers on the buccal absorption of hybrid (BDBB) α-interferon, Int. J. Pharm. 104 (1994) 145-149.
16. [16] Y. Nakada. N. Awata, C. Nakamichi and S. Goto, The effects of additives on the oral mucosal absorption of human calcitonin in rats, J. Pharmacobio-Dyn. 11 (1988) 395-401.
17. [17] C.D. Ebert, S.J. Heiber, S.C. Dave, S.W. Kim and D. Mix, Mucosal delivery of macromolecules, J. Control. Release 28 (1994) 37-44.
18. [18] B.A. Burnside, A.D. Keith and W. Snipes, Microporous hollow fibers as a peptide delivery system via the buccal cavity. Proceed. Int. Symp. Control. Rel. Bioact. Mater. 16 (1989) 93-94.
19. [19] V.H.L. Lee, A. Yamamoto and U. Bhaskar, Mucosal penetration enhancers for facilitation of peptide and protein drug absorption, Crit. Rev. Ther. Drug Carrier Syst. 8 (1991) 91-192.
20. [20] M. Ishida, Y. Machida, N. Nambu and T. Nagai, New mucosal dosage form of insulin, Chem. Pharm. Bull. 29 (1981) 810-816.
21. [21] Y. Nakada, N. Awata, Y. Ikuta and S. Goto, The effects of bile salts on the oral mucosal absorption of human calcitonin in rats, J. Pharmacobio-Dyn. 12 (1989) 736-743.
22. [22] J. Pitha, S.M. Harman and M.E. Michel, Hydrophilic cyclodextrin derivatives enable effective oral administration of steroidal hormones, J. Pharm. Sci. 75 (1986) 165-167.
23. [23] R. Gandhi and J.R. Robinson. Mechanisms of penetration enhancement for transbuccal delivery of salicylic acid, Int. J. Pharm. 85 (1985) 129-140.
24. [24] J. Sandow, G. Jerabek-Sandow, B. Krauss and M. Schmidt-Gollwitzer, Pharmacokinetics and metabolism of LHRH agonists, clinical aspects, in: F. Labrie, A. Belanger and A. Dupont (Eds.), LHRH and its analogues, Elsevier Science Publ., Amsterdam 1984, pp. 123-137.
25. [25] J. Sandow and W. Petri. Intranasal administration of peptides, biological activity and therapeutic efficacy, in: Y.W. Chien (Ed.), Transnasal systemic medications, Elsevier Science Publ., Amsterdam, 1985, pp. 183-199.
26. [26] A.J. Hoogstraate. J.C. Verhoef, B. Tuk, A. Pijpers, L.A.M.G. van Leengoed. J.H.M. Verheijden, H.E. Junginger and H.E. Boddé, In-vivo buccal delivery of fluorescein isothiocyanate-dextran 4400 with glycodeoxycholate as an absorption enhancer in pigs, J. Pharm. Sci. 85 (1996) 457-460.
27. [27] C.A Lesch, C.A. Squier, A. Cruchley, D.M. Williams, and P. Speight, The permeability of human oral mucosa and skin to water, J. Dent. Res. 68 (1989) 1345-1349.
28. [28] A.J. Hoogstraate, S. Senel, C. Cullander, J.C. Verhoef, H.E. Junginger, H.E. Boddé, Effects of bile salts on transport rates and routes of FITC-labelled compounds across porcine buccal epithelium in-vitro, J. Control. Release (1996) in press.
29. [29] H.M. Behre. J. Sandow and E. Nieschlag, Pharmacokinetics of the gonadotropin-releasing hormone agonist buserelin after injection of a slow-release preparation in normal men, Arzneim.-Forsch./Drug Res. 42 (1992) 80-84.
30. [30] J.P. Cassidy, N.M. Landzert and E. Quadros, Controlled buccal delivery of buprenorphine, J. Control. Release 25 (1993) 21-29.